 | |
- close
- close
|
Business Wire
Nov 16
Comment
ArQule, Inc. (Nasdaq: ARQL) today presented data at the AACR-NCI-EORTC meeting in Boston demonstrating the capabilities of the Company’s proprietary drug discovery platform to generate a class of small molecules with significant therapeutic
StreetInsider.com
Nov 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/ArQule+%28ARQL%29+Posts+Q3+Loss+of+%240.18%2C+Beats+Estimates%3B+Reaffirms+Guidance/5078091.html for the full story.
Business Wire
Nov 5
Comment
ArQule, Inc. (NASDAQ: ARQL) today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009. The Company reported a net loss of $8,088,000 or $0.18 per share, for the quarter ended September 30, 2009, compared
Business Wire
Oct 29
Comment
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the third quarter of 2009 in a press release to be issued on Thursday, November 5, 2009 at 7:00 a.m. eastern time. The Company will host a conference call and
Business Wire
Oct 27
Comment
ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009 at 4:30 p.m. eastern time. ArQule’s presentation will be web cast live and can be accessed through
Business Wire
Oct 15
Comment
ArQule, Inc. (Nasdaq: ARQL) today announced that a presentation at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in Boston on November 16, 2009, will highlight the discovery of potent, small molecule
Business Wire
Oct 14
Comment
ArQule, Inc. (NASDAQ: ARQL) today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma. Under the guidelines of the EMEA, medicinal products are
StreetInsider.com
Oct 13
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/UBS+Upgrades+ArQule+%28ARQL%29+Two+Notches+to+Buy/5011378.html for the full story.
Business Wire
Oct 5
Comment
ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed. Approximately 160 patients were enrolled in the NSCLC trial, which is a randomized,
Business Wire
Sep 14
Comment
ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the UBS Global Life Sciences Conference on Monday, September 21, 2009 at 10:30 a.m. eastern time. ArQule’s presentation will be web cast live and can be accessed through the
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
ARQL AT A GLANCE
References
| ||||||
|
|
